drugset / Trial / NCT01247818

Randomized Study of PH-10 for Psoriasis

NCT01247818

Phase 2 Completed 99 enrolled Provectus Pharmaceuticals
RandomizedParallel-groupSingle-blindTreatment

Summary

PH-10 is an aqueous hydrogel formulation of rose bengal disodium (RB) for topical administration to the skin, and is being studied for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis. This multicenter phase 2 study of subjects randomized sequentially by center to one of four treatment cohorts will assess efficacy and safety of topical PH-10 applied once daily to areas of mild to moderate plaque psoriasis.

Timeline

Start
2010-12
Primary completion
2011-08
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject rose bengal disodium Unknown 0.002 % Topical
Subject rose bengal disodium Unknown 0.005 % Topical
Subject rose bengal disodium Unknown 0.01 % Topical

Indications